Zoetis Inc. (ZTS)
Zoetis is a global animal health company that discovers, develops, manufactures and commercializes medicines, vaccines and diagnostics for pets and livestock.
| Ticker | ZTS |
|---|
| Company | Zoetis Inc. |
|---|
| Exchange | NYSE |
|---|
| Headquarters | PARSIPPANY, NJ |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $667,000,000 |
|---|
| Cost of Goods and Services Sold | $673,000,000 |
|---|
| Earnings Per Share, Basic | 2 USD/shares |
|---|
| Earnings Per Share, Diluted | 2 USD/shares |
|---|
| Gross Profit (derived) | $1,795,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $866,000,000 |
|---|
| Income Tax Expense (Benefit) | $175,000,000 |
|---|
| Interest Expense | $61,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | $691,000,000 |
|---|
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 |
|---|
| Nonoperating Income (Expense) | $5,000,000 |
|---|
| Other Nonoperating Income (Expense) | -$2,000,000 |
|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $691,000,000 |
|---|
| Restructuring Charges | $95,000,000 |
|---|
| Revenues | $2,468,000,000 |
|---|
| Selling, General and Administrative Expense | $592,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $51,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 417,700,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 417,600,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro